Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Role of dual PI3/Akt and mTOR inhibition in Waldenstrom s Macroglobulinemia Sacco A; Roccaro A; Ghobrial IMOncotarget 2010[Nov]; 1 (7): 578-582Tumorigenesis occurs due to synergistic interactions from a complex of signal transduction processes, including multiple onco-proteins and tumor suppressors such as Ras, Myc, PI3K/Akt/mTOR, Her-2/Neu, p53 and PTEN. Specifically, the PI3K/Akt and mTOR pathways have been shown to play a pivotal role on the initiation and progression of malignancies, enhancing cell survival by stimulating cell proliferation, and inhibiting apoptosis. Therefore, it is critical to examine therapeutic agents that explicitly target both the PI3K/Akt and mTOR signaling cascades in diseases, such as Waldenstrom Macroglobulinemia (WM), that harbor activation of the PI3K/Akt pathway. We demonstrated that dual targeting of the PI3K and mTOR pathways by the novel inhibitor NVP-BEZ235, exhibited toxicity on WM cells by directly targeting the tumor clone and indirectly through an effect on the bone marrow milieu. These findings suggest that dual targeting of the PI3K and mTOR pathways is a better modality of targeted therapy for tumors that harbor activation of the PI3K/mTOR pathways, such as in WM.|*Phosphoinositide-3 Kinase Inhibitors[MESH]|Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]|Humans[MESH]|Molecular Targeted Therapy/methods[MESH]|Phosphatidylinositol 3-Kinases/physiology[MESH]|Protein Kinase Inhibitors/*administration & dosage/pharmacology[MESH]|Proto-Oncogene Proteins c-akt/*antagonists & inhibitors/physiology[MESH]|Signal Transduction/drug effects/physiology[MESH]|TOR Serine-Threonine Kinases/*antagonists & inhibitors/physiology[MESH]|Treatment Outcome[MESH]|Waldenstrom Macroglobulinemia/*drug therapy[MESH] |
